Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
TBC etonogestrel Prevention of pregnancy Withdrawn
Tecentriq Atezolizumab Withdrawn
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
TBD Entrectinib Withdrawn
Atriance Nelarabine Cancelled
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Withdrawn
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
Ikervis cyclosporine keratitis, severe Withdrawn
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
TBD Cabozantinib Withdrawn
Breo Ellipta fluticasone furoate/vilanterol Asthma Withdrawn
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn
Admelog Insulin lispro Cancelled
Erbitux Cetuximab Cancelled
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn
TBD Bevacizumab Cancelled
TBD Rituximab Cancelled
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
TBC halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Withdrawn
Ogivri Trastuzumab Withdrawn
Zytiga Abiraterone Withdrawn
Aduhelm aducanumab Alzheimer’s disease Withdrawn